STOCK TITAN
  1. Home
  2. News
  3. IVVD

Invivyd Inc - IVVD STOCK NEWS

IMPACT
SENTIMENT
IVVD : Nasdaq
Invivyd Publishes Model for Evaluating Biomarker Correlates of Protection for Monoclonal Antibodies Against Symptomatic COVID-19
covid-19
IMPACT
SENTIMENT
IVVD : Nasdaq
Invivyd to Host Conference Call Discussing Full Year 2022 Financial Results and Business Highlights
conferences earnings
IMPACT
SENTIMENT
IVVD : Nasdaq
Invivyd Optimizes Development Efficiency with Election of VYD222 for Near-Term Clinical Advancement to Address Urgent Unmet Need for COVID-19 Monoclonal Antibodies
covid-19
IMPACT
SENTIMENT
IVVD : Nasdaq
Investors purchased NASDAQ: IVVD shares between November 29 and December 14, 2021, should contact the Shareholders Foundation in connection with the Lawsuit against Invivyd, Inc.
IMPACT
SENTIMENT
IVVD : Nasdaq
Invivyd to Participate at Cowen’s 43rd Annual Healthcare Conference
conferences
IMPACT
SENTIMENT
IVVD : Nasdaq
Invivyd Announces Changes to Executive Team
IMPACT
SENTIMENT
IVVD : Nasdaq
Invivyd Presented Joint Industry Rationale on Potential Expedited Development Pathways for Monoclonal Antibodies at FDA-EMA Workshop
IMPACT
SENTIMENT
IVVD : Nasdaq
Invivyd Appoints Jeremy Gowler as Chief Operating and Commercial Officer, Promotes Pete Schmidt, M.D., to Chief Medical Officer
management
IMPACT
SENTIMENT
IVVD : Nasdaq
Invivyd Announces Partnership With Population Health Partners to Accelerate Clinical Development in Infectious Diseases Including COVID-19
partnership clinical trial covid-19
IMPACT
SENTIMENT
IVVD : Nasdaq
Invivyd Reports Third Quarter 2022 Financial Results and Business Highlights
earnings
Stock IVVD logo
Invivyd Inc

Nasdaq:IVVD

IVVD Rankings

#4563 Ranked by Market Cap
#4901 Ranked by Stock Gains
N/A Ranked by Dividends

IVVD Stock Data

Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States
Waltham

About IVVD

adagio is developing best-in-class antibodies that can broadly neutralize sars-cov-2, sars-cov-1 and additional potentially emergent coronaviruses. we believe our antibodies will match or exceed the potency and coverage of conventional sars-cov-2 antibody programs and can be used as both therapeutic and durable prophylactic treatments. our candidates are engineered using best-in-industry antibody discovery capabilities and are designed to maximize potency and duration of effect. our portfolio includes multiple, non-competing antibodies with distinct binding targets, enabling a strategy that can avoid viral escape. our lead program is expected to enter the clinic by the end of 2020.